In recent years, as the critical role of macrophages in the progression of NAFLD and NASH has been further elucidated, therapeutic strategies such as CCR2/CCR5 dual antagonists and TREM2 inhibitors have shown promising results in preclinical and clinical trials. The gene discussed is TREM2; the disease is metabolic dysfunction-associated steatohepatitis.